Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495803 | 0.86 | MRGPRX4 (0.46) | NR4A2MAPTMRGPRX4MAOBGRM5 | |
| SCHEMBL3494813 | 0.73 | NOTUM (0.48) | NR4A2MAPTMRGPRX4MAOBGRM5 | |
| SCHEMBL3493113 | 0.73 | NOTUM (0.53) | NR4A2MAPTMRGPRX4MAOBGRM5 | |
| SCHEMBL3493854 | 0.72 | DCTPP1 (0.46) | MAPTNOTUMMEN1KMT2AKDM4E | |
| SCHEMBL3493945 | 0.72 | PTGER1 (0.42) | MAPTMRGPRX4PTGER1ALKBH1PTGER4 | |
| SCHEMBL3386778 | 0.71 | KDM4E (0.73) | MAPTMEN1KMT2ASRD5A2KDM4E | |
| SCHEMBL3494269 | 0.69 | POLB (0.60) | NR4A2MAPTMRGPRX4MAOBGRM5 | |
| SCHEMBL4450809 | 0.68 | NR4A2 (0.58) | NR4A2MRGPRX4MAOBMEN1KMT2A | |
| SCHEMBL3495799 | 0.67 | JAK2 (0.55) | MAPTMRGPRX4MAOBNOTUMMEN1 | |
| SCHEMBL6087956 | 0.67 | PTGER4 (0.55) | NR4A2MRGPRX4MAOBPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | NR4A2 1564/4885MAPT 4821/4885MRGPRX4 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.